18F-FDG PET versus 18F-FDG PET/CT for Adrenal Gland Lesion Characterization: a Comparison of Diagnostic Efficacy in Lung Cancer Patients

Yon Mi Sung, MD1,2
Kyung Soo Lee, MD1
Byung-Tae Kim, MD3
Joon Young Choi, MD3
Myung Jin Chung, MD1
Young Mog Shim, MD4
Chin A Yi, MD1
Tae Sung Kim, MD1

Index terms:
18F-FDG
PET
PET/CT
Lung cancer
Adrenal metastasis

DOI:10.3348/kjr.2008.9.1.19
Korean J Radiol 2008; 9: 19-28
Received September 18, 2007; accepted after revision May 14, 2007.

1Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea; 2Department of Medical Imaging, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 3Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea; 4Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea

This work was presented at the 2005 RSNA scientific assembly (Paper number SSC21-08). A Korean Research Foundation Grant (KRF-2004-003-D00246) supported this study.

Address reprint requests to:
Kyung Soo Lee, MD, Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Ilwon-dong, Kangnam-gu, Seoul 135-710, Korea.
Tel. (822) 3410-2518
Fax. (822) 3410-2559
e-mail: kyungs.lee@samsung.com

Objective: The aim of this study was to assess the diagnostic efficacy of integrated PET/CT using fluorodeoxyglucose (FDG) for the differentiation of benign and metastatic adrenal gland lesions in patients with lung cancer and to compare the diagnostic efficacy with the use of PET alone.

Materials and Methods: Sixty-one adrenal lesions (size range, 5 – 104 mm; mean size, 16 mm) were evaluated retrospectively in 42 lung cancer patients. Both PET images alone and integrated PET/CT images were assessed, respectively, at two-month intervals. PET findings were interpreted as positive if the FDG uptake of adrenal lesions was greater than or equal to that of the liver, and the PET/CT findings were interpreted as positive if an adrenal lesion showed attenuation > 10 HU and showed increased FDG uptake. Final diagnoses of adrenal gland lesions were made at clinical follow-up (n = 52) or by a biopsy (n = 9) when available. The diagnostic accuracies of PET and PET/CT for the characterization of adrenal lesions were compared using the McNemar test.

Results: Thirty-five (57%) of the 61 adrenal lesions were metastatic and the remaining 26 lesions were benign. For the depiction of adrenal gland metastasis, the sensitivity, specificity, and accuracy of PET were 74%, 73%, and 74%, respectively, whereas those of integrated PET/CT were 80%, 89%, and 84%, respectively (p values; 0.5, 0.125, and 0.031, respectively).

Conclusion: The use of integrated PET/CT is more accurate than the use of PET alone for differentiating benign and metastatic adrenal gland lesions in lung cancer patients.

Adrenal metastases are frequently noted in patients with lung cancer (1); however, the majority of adrenal lesions are likely to be benign, even in lung cancer patients (2 – 5). The reported incidence of adrenal lesions in lung cancer patients, regardless as to whether they are due to metastasis, varies from 4% to 18% in clinical studies (3, 6, 7), and up to 40% of these lesions may be malignant and present as solitary sites of metastasis (8). Therefore, it is essential to differentiate between benign and malignant lesions in lung cancer patients to ensure optimal management. The percutaneous biopsy is the gold standard for confirming the status of adrenal lesions, but is invasive and difficult to perform, and thus frequently leads to complications or study failure (9).

Noninvasive imaging methods have been examined in terms of their abilities to determine adrenal lesion status. Chemical shift MR imaging is found to be useful for differentiating between benign and malignant adrenal lesions (10, 11). CT has proven useful in this context because of its ability to measure attenuation, on both unenhanced images and on delayed contrast-enhanced images (12–14). The use of
\(^{18}\)Fluorine-fluorodeoxyglucose (FDG) PET has also shown encouraging results (15–20), but relatively few studies have addressed the usefulness of FDG PET for evaluating adrenal lesions specifically in patients with lung cancer (15, 16, 19).

Recently, the development of integrated PET/CT has allowed functional PET and anatomical CT images to be obtained in one session. The combination of PET and CT data sets using the integrated PET/CT approach is not additive; in fact, it is highly synergistic (21–23). The limited ability of PET to localize accurately lesions, due to a lack of precise anatomical landmarks, has been demonstrated by several studies (24–28). However, several recent studies on the accuracy of PET/CT versus PET have shown that PET/CT helps resolve this problem for ambiguous lesions, especially for anatomy-related lesions (26, 29–33). However, no study has yet addressed the usefulness of integrated PET/CT for differentiating benign and metastatic adrenal lesions in lung cancer patients. Our goal was to assess the diagnostic efficacy of integrated \(^{18}\)F-FDG PET/CT for the differentiation of benign and metastatic adrenal gland lesions in lung cancer patients and to compare these results with the use of \(^{18}\)F-FDG PET alone.

**MATERIALS AND METHODS**

Our institutional review board approved this research study. Patient informed consent was not required for the retrospective study, but written informed consent was obtained from all patients for obtaining the integrated FDG PET/CT study.

**Patients and the Characteristics of Adrenal Lesions**

From May 2003 to July 2005, we treated 53 lung cancer patients with uncharacterized adrenal lesion(s) detected by contrast-enhanced thoracic (covering from thoracic inlet to middle portion of both kidneys) CT. During the same period, 1,283 new lung cancer patients were registered at our institution. An adrenal gland lesion was considered present when a round or oval lesion (short- and long-axis diameters were within a factor of 1.5 of each other) with a discrete margin was identified in the adrenal gland. When diffuse enlargement without nodule formation was identified, the abnormality was considered hyperplastic and was not included. Patients that had undergone integrated PET/CT were studied before the initiation of chemotherapy or radiation therapy to avoid any potential effects of the therapies as seen by adrenal \(^{18}\)F-FDG uptake. Eleven of the 53 patients were excluded because of a short clinical follow-up period of < 6 months for nine patients and follow-up loss for two patients. Therefore, we included 42 patients (38 men and 4 women; age range 33–77 years; mean ± standard deviation [SD], 62 ± 8.9 years).

Of these 42 patients, 38 underwent PET/CT once. The 38 patients had a total of 52 adrenal gland lesions; 26 patients had a single unilateral adrenal gland lesion, 10 patients had two lesions (one each lesion in each gland) bilaterally, and two patients had three lesions (one in one gland and two in the other gland), also bilaterally. Four patients underwent FDG PET/CT twice at intervals of two months for two patients, of an interval of 11 months in one patient, and an interval of 14 months in the remaining one patient. In one of these four patients, a unilateral lesion was present at the initial study and bilateral lesions were detected at the follow-up study. Therefore, counting the adrenal lesions in each study, nine lesions (six from three patients and three from one patient) from these four patients were also included in the study. Including the nine lesions in these four patients, 61 adrenal lesions in 42 patients were the targets of this study.

Histological analyses showed that the primary lung cancers were adenocarcinomas in 24 patients, squamous cell carcinomas in 15 patients, small cell carcinomas in two patients, and a large cell neuroendocrine carcinoma in one patient. A total of 61 adrenal lesions in 42 patients were evaluated using contrast-enhanced standalone CT reports. All patients underwent integrated PET/CT for the primary tumor characterization and the staging of histologically-proven lung cancer.

The final diagnoses of adrenal lesions were reached by clinical follow-ups (n = 52) or by histopathological examinations (n = 9) of surgical specimens, when available. In the clinical follow-up studies, an adrenal lesion was considered benign if it did not show any change in size for at least six months (mean ± SD for 20 presumed benign adrenal lesions, 14 ± 7 months; range, 6–28 months; median, 12 months). A lesion was considered malignant if it showed an increase or decrease in size after treatment (≥ 3 mm change in the longest diameter).

**Integrated PET/CT Acquisition**

All patients fasted for at least six hours before the PET/CT examination, although oral hydration with glucose-free water was allowed. After ensuring a normal blood glucose level in the peripheral blood, patients received an intravenous injection of 370 MBq (10 mCi) of FDG and then rested for approximately 45 minutes before scanning. Scans were acquired using a PET/CT device (Discovery LS; GE Medical Systems, Milwaukee, WI), which consisted of a PET scanner (Advance NXi; GE Medical Systems) and an eight-section CT scanner.
(LightSpeed Plus; GE Healthcare). The axes of both systems were mechanically aligned such that a patient could be moved from the CT scanner to the PET scanner gantry by moving the examination table by 68 cm.

CT was performed from the head to the pelvic floor according to a standardized protocol using the following settings: 140 kVp; 80 mA; tube rotation time, 0.5 seconds per rotation; pitch, 6; and section thickness, 5 mm (to match the PET section thickness). Patients maintained normal shallow respiration during the acquisition of CT scans. Iodinated contrast material was not administered. Immediately after the unenhanced CT scan, an emission PET scan was performed in the identical transverse field of view. The acquisition time for PET was 5 minutes per table position (each frame). The CT data were resized from a 512 × 512 matrix to a 128 × 128 matrix to match the PET section thickness. Patients maintained normal shallow respiration during the acquisition of CT scans. Iodinated contrast material was not administered.

According to previous studies (15, 17), visual assessment of suspected lesions was just as effective at differentiating active from inactive disease as quantitative analysis using a standardized uptake value (SUV). Therefore, the maximum SUV was not used to differentiate benign and malignant adrenal lesions.

When interpreting the integrated PET/CT images, we also assessed CT component of the adrenal lesions in addition to the PET component of the lesions. The longest diameter of adrenal lesion was measured where it appeared largest on the transverse images. We also recorded the attenuation value of the adrenal lesions. A region of interest, ovoid or circular, covering between one-half to two-thirds of the largest area within the adrenal lesion, was selected. For each of the adrenal lesions, average attenuation values (mean of two measurements) and SDs were obtained.

When lesions had ≤ 10 HU, all adrenal lesions, regardless of the FDG uptake value, were interpreted as benign. When lesions had > 10 HU attenuation value, they were regarded as metastatic with an FDG uptake greater than or equal to that of the liver and as benign with an FDG uptake less than that of the liver. After the image reading sessions, maximum SUVs were recorded if the FDG uptake of the adrenal lesion was considered present at the integrated PET/CT examination. The nodule sizes of the benign and metastatic adrenal lesions were also recorded.

**Statistical Analysis**

The accuracies, sensitivities, and specificities of PET and PET/CT for the diagnosis of adrenal metastases were assessed using a generalized estimating equation. We regarded each case in which there was agreement between the final diagnosis and the image interpretation as positive, and similarly, each case in which there was disagreement as negative. The diagnostic accuracies of both methods for the diagnosis of adrenal metastasis were compared using the McNemar test. Differences in the maximum SUVs, the nodule sizes, and attenuation values of benign and metastatic adrenal lesions were also recorded.

**RESULTS**

The sizes of the adrenal lesions on CT scans ranged from 5 to 104 mm in the longest diameter, with a mean of 16
mm and a median of 13 mm.

**Benign versus Malignant Adrenal Lesions**

Thirty-five (57%) of the 61 adrenal lesions eventually were proved to be metastatic adrenal disease, either by surgery (n = 3) or clinical follow-up (n = 32). The remaining 26 adrenal lesions were benign, as determined either by surgery (n = 6) or by at least six months of clinical follow-up (n = 20). Histopathological examinations of the benign adrenal lesions demonstrated the presence of adenomas (n = 5) and endothelial cysts (n = 1). Overall, the mean sizes (± SD) of the 61 adrenal lesions were 16 ± 15 mm (range: 5–104 mm). The mean lesion sizes (± SD) were 13 ± 8 mm for the benign lesions and 18 ± 17 mm for the malignant lesions (p = 0.187) (Table 1). The mean attenuation values (± SD) were 12.4 ± 11.1 for the benign lesions and 29.7 ± 10.9 for the malignant lesions (p

| Size Range | Malignant (n = 35) | Benign (n = 26) |
|------------|-------------------|-----------------|
|            | < 10 mm*          | < 10 mm         |
|            | (n = 9)           | (n = 15)        |
| PET alone  | 4/9 (44%)         | 11/15 (73%)     |
| Integrated PET/CT | 4/9 (44%) | 14/15 (93%) |

Table 1. Size Distribution of the Malignant and Benign Adrenal Gland Lesions and the Correctly Diagnosed Rates According to the Sizes Determined by the Use of PET Alone and with Integrated PET/CT

Note.—At PET, *a nodule as small in its longest diameter of 5 mm was correctly diagnosed as malignant and a nodule as large in its longest diameter of 38 mm was correctly diagnosed as benign. D = diameter

**Table 1.** A false-positive interpretation with the use of PET only, but a true negative interpretation with the use of integrated PET/CT in a 57-year-old man with adenocarcinoma in the right upper lobe of the lung.

**A.** PET demonstrates increased uptake (arrow) in the right adrenal gland area with a maximum standardized uptake value of 3.2. PET alone regarded the uptake as positive.

**B.** Unenhanced CT scan shows hepatic cysts (arrowheads).

**C.** On an integrated PET/CT image, the uptake (arrow) falls on the liver, thus enabling a correct interpretation as negative uptake in the right adrenal gland.
< 0.001), and the mean maximum SUV (± SD) values were 1.7 ± 1.84 for the benign lesions and 7.2 ± 5.13 for the malignant lesions (p < 0.001).

Diagnostic Efficacy of PET alone versus Integrated PET/CT

The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET for the detection of metastatic disease were 74% (26 of 35 lesions), 73% (19 of 26 lesions), 79% (26 of 33 lesions), 68% (19 of 28 lesions), and 74% (45 of 61 lesions), respectively. The corresponding values for sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for PET/CT were 80% (28 of 35 lesions), 89% (23 of 26 lesions), 90% (28 of 31 lesions), 77% (23 of 30 lesions), and 84% (51 of 61 lesions), respectively. Thus, the accuracy for PET/CT (84%, 51 of 61 lesions) was significantly higher than that for PET (74%, 45 of 61 lesions) (p = 0.031). However, the values of sensitivity (p = 0.5) and specificity (p = 0.125) for PET/CT were not significantly different from the values for PET.

Causes of False Lesion Interpretations

For the PET images alone, seven false positive interpretations were made for two adenomas that were proven at surgery, for one endothelial cyst that was proven at surgery, for two misinterpretations of hepatic uptakes as adrenal gland uptakes (Fig. 1), and for two misinterpretations of lymph node uptakes as adrenal gland uptakes. For nine false negative interpretations made, the mean size and mean maximum SUV value of the adrenal lesions were 8 mm (range, 5 – 13 mm) and 1.6 (range, 0 – 4.5), respectively (Table 1).

For the integrated PET/CT images, three false positive interpretations were made, and these stemmed from two adrenal adenomas (Fig. 2) and one endothelial cyst (Fig. 3) in the adrenal glands. For the seven false negative interpretations made, the mean size and mean maximum SUV

Fig. 2. A false-positive interpretation by the use of both PET and PET/CT in a 33-year-old woman with an adrenal adenoma that was confirmed by surgical excision. The patient also had an adenocarcinoma in the left lower lobe of the lung.
A. PET demonstrates increased uptake (arrow) in the left adrenal gland lesion with a maximum standardized uptake value of 4.6.
B. An unenhanced CT scan shows a 14 mm sized nodule (arrow) in the left adrenal gland.
C. Integrated PET/CT shows high uptake (arrow) in the nodule of the left adrenal gland.
value were 7 mm (range, 5–11 mm) and 1.0 (range, 0–2.4), respectively (Table 1).

PET and PET/CT made six discordant interpretations. In four cases, PET produced a false-positive result because FDG uptake in the liver or lymph nodes was misinterpreted as adrenal uptake. In one case in which a patient underwent FDG PET/CT twice with a two-month interval, false-negative results we obtained by PET and by PET/CT at the initial study. However, at the follow-up study, PET continued to show a false-negative result, but PET/CT produced a true-positive result. In this particular case, the adrenal lesion was 6 mm in diameter as determined at the initial study and 11 mm in diameter as determined at the second study. In the remaining single case, a nodule was regarded as benign by PET as the adrenal uptake was interpreted as uptake in the adjacent left kidney, whereas it was correctly interpreted as metastasis by the use of integrated PET/CT (Fig. 4).

**DISCUSSION**

CT is the primary diagnostic imaging method for adrenal gland lesion evaluation. Lipid within adenomas causes low attenuation in unenhanced CT images. In addition, adenomas demonstrate rapid washout after intravenous contrast administration (12–14). The sensitivity and specificity of unenhanced CT (at a threshold attenuation of ≤ 10 HU) for distinguishing an adenoma from other diseases has been determined as 79% and 96%, respectively (13). The sensitivity, specificity, and diagnostic accuracy as reported by a dynamic study were 98%, 92%, and 96%, respectively (12).

Signal intensity on T2-weighted and chemical shift imaging using signal intensity reductions between in-phase and opposed-phase MR images were initially investigated in an effort to differentiate benign from malignant lesions. However, benign and malignant lesions were found to
overlap considerably in terms of signal intensity (10, 11, 34). Burt et al. (8) reported a false-positive level for unilateral adrenal masses of 67% in patients with operable non-small cell lung cancer, i.e., 14 of 21 histologically benign masses were interpreted as malignant masses based on the relative signal strengths of T1- and T2-weighted images.

Unlike CT and MRI, FDG PET intensities are dependent on the glucose metabolism in the malignant lesions. FDG PET in patients with lung cancer and adrenal masses has reported ranges for sensitivities of 93–100%, specificities of 80–100%, and diagnostic accuracies of 92–100% (15–20). However, the limited accuracy of lesion localization using PET alone, due to the lack of precise anatomical landmarks, has been demonstrated by several previous studies (24–28).

Recently, integrated ¹⁸F-FDG PET/CT was introduced. This technique can produce directly functional PET and anatomical CT images in one session. Integrated ¹⁸F-FDG PET/CT findings are not simply the summation of PET and CT findings; in fact they are the result of a high level of synergism between the two modalities (21–23). Previous studies that have evaluated the accuracy of PET/CT versus PET have shown that rate of ambiguous lesions findings is lower for the use of PET/CT (26, 29–33). In the present

**Fig. 4.** A false-negative interpretation with the use of PET only, but a true positive interpretation with the use of integrated PET/CT in a 33-year-old woman with an adrenal metastasis confirmed by clinical follow-up. The patient also had adenocarcinoma in the right lower lobe of the lung.

A. PET demonstrates increased uptake (arrow) in the left adrenal gland area with a maximum SUV of 3.5. Uptake was regarded as benign by PET alone because the uptake was interpreted as left kidney uptake.

B. An unenhanced CT scan shows an 11-mm-sized nodule (arrow) in the left adrenal gland.

C. On an integrated PET/CT image, the uptake (arrow) falls on the left adrenal gland, thus enabling a correct interpretation as positive uptake (uptake extent is equal to that of liver).

D. The nodule (arrow) in the left adrenal gland shows an increase in size at a 7-month follow-up CT. Hepatic metastasis is also noted (arrowhead).
In this study, the FDG uptake of an adrenal lesion was compared with that of liver, thus an adrenal lesion was interpreted as positive for metastasis if the FDG uptake was greater or equal to that of the liver. However, Bagheri et al. (35) addressed that normal adrenal glands show a wide range of FDG uptake and can demonstrate uptake equal to or slightly greater than liver activity. Interestingly, image interpretations using an attenuation value combined with FDG uptake was less than in the liver and as benign with the FDG uptake was greater than in the liver and as benign with the FDG uptake was less than in the liver. Interestingly, image interpretations using an attenuation value combined with FDG uptake were not different with image interpretations only using FDG uptake. Moreover, the sensitivity and specificity of the CT component of the integrated PET/CT (at a threshold attenuation of ≤ 10 HU) for the diagnosis of adrenal metastasis, excluding FDG uptake, were 94% and 35%, respectively. These findings indicate a discrepancy between the current and previously published studies (13), namely, a relatively higher sensitivity and relatively much lower specificity of the unenhanced CT. The discrepancy may be explained by the use of different CT techniques. In this study, attenuation values were measured on the CT component of integrated PET/CT images that were obtained using lower killovoltage (140 kVp) and milliamperage (80 mA) settings compared to the settings employed for conventional CT techniques. Therefore, beam-hardening artifacts more frequently developed and the attenuation values of the adrenal lesions were measured with higher values, especially for the small sized adrenal lesions. We provisionally regarded the CT component of the integrated PET/CT as not useful for the diagnosis of adrenal metastasis.

In contrast to previously published studies for 18F-FDG PET, the present results showed a lower sensitivity, specificity, and diagnostic accuracy. There are several possible reasons to explain these results. First, the adrenal lesions of relatively small sizes were included in this study; the overall mean size (± SD) and median of 61 adrenal lesions were 16 ± 15 mm (range; 5 – 104 mm) and 13 mm, respectively. In previous studies, the mean sizes of the adrenal lesions were 20 ± 10 mm (range; 5 – 42 mm) (18), 26 mm (range; 5 – 54 mm) (15), 24 ± 16 mm (range; 6 – 110 mm) (32), and 20 mm (range; 5 – 95 mm) (33), respectively. In this study, CT images were obtained using a multi-detector row CT, which could provide much thinner-section CT images and thus help detect small-sized adrenal gland lesions. Previous studies (16 – 20) were performed before the development of multi-detector row CT. Second, we included cases of rather long mean follow-up periods, thus, we might have more accurate reference standard values. For example, in this study, 20 benign adrenal lesions had a 14 ± 7 month follow-up period. Additionally, two malignant adrenal lesions, which were erroneously diagnosed as benign by PET (with the use of integrated PET/CT, one lesion was wrongly diagnosed and the other was correctly diagnosed), showed a detectable increase in their sizes at studies performed seven months and 12 months after the initial studies, respectively. In previous studies, their mean follow-up period for making a benign diagnosis for the adrenal lesions could not be identified (15, 18).

The commonly reported causes of false-positive results have been due to pheochromocytomas and benign adenomas (18, 36). There were three cases of false-positive findings shown by integrated PET/CT in the present study. Two cases were due to benign adenomas and one case to an endothelial cyst. The cause of the uptake in the endothelial cyst was unclear.

Commonly reported causes of false-negative results are a small lesion size, necrotic metastases, and metastases from neuroendocrine tumors (18, 37). In the present study, there were seven false-negative integrated PET/CT interpretations, and all were due to small lesion size (range 5 – 11 mm; mean 7 mm).

One potential limitation of this study is that a biopsy was not performed in all cases. Therefore, we may have missed cases of micrometastasis or slow-growing metastatic lesions in the adrenal gland. Moreover, there might have been metastatic lesions that did not show any size change as chemotherapy hampered lesion growth. This is an inherent drawback in all studies of this type, because not all adrenal lesions can be proven histopathologically. In addition, cortisol, dehydroepiandrosterone, and sex hormone levels were not determined to examine the possibility of stress-induced adrenal activation.
FDG PET versus FDG PET/CT for Adrenal Gland Lesion Characterization in Lung Cancer

In conclusion, the use of integrated PET/CT using FDG was found to provide 80% sensitivity, 89% specificity, and 84% accuracy for the characterization (metastatic versus benign) of CT-positive adrenal gland lesions in lung cancer patients, and was found to be more accurate than the use of PET alone.

References

1. Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J Clin Oncol 1991;9:1462-1466
2. Hedeland H, Ostberg G, Hokfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968;184:211-214
3. Chapman GS, Kumar D, Redmond J 3rd, Munderloh SH, Gandara DR. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer 1984;54:1541-1543
4. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950;3:74-85
5. Oliver TW Jr, Bernardino ME, Miller JJ, Mansour K, Greene D, Davis WA. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984;153:217-218
6. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal thomors: an institutional perspective. Surgery 1991;110:1014-1021
7. Porte HL, Roumilhac D, Graziana JP, Eraldi L, Cordonier C, Puech P, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 1998;65:331-335
8. Burt M, Heelan RT, Coit D, McCormack PM, Bains MS, Martini N, et al. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg 1994;107:584-589
9. Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 1995;19:434-439
10. Namimoto T, Yamashita Y, Mitsuzaki K, Nakayama Y, Makita O, Kadota M, et al. Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas. Radiology 2001;218:642-646
11. Tsushima Y, Ishizaka H, Matsumoto M. Adrenal masses: differentiation with chemical shift, fast low-angle shot MR imaging. Radiology 1993;186:705-709
12. Caolli EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-633
13. Lee MJ, Hahn PF, Papanicolau N, Egglin TK, Saini S, Mueller PR, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991;179:415-418
14. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000;217:798-802
15. Kumar R, Xiu Y, Yu QJ, Takalkar A, El-Haddad G, Potenta S, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004;45:2058-2062
16. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-1360
17. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-134
18. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-1799
19. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer 2001;3:59-64
20. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999;173:25-29
21. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379
22. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med 2003;33:193-204
23. Townsend DW. A combined PET/CT scanner: the choices. J Nucl Med 2001;42:533-534
24. von Schulthess GK. Positron emission tomography versus positron emission tomography/computed tomography: from “unclear” to “new-clear” medicine. Mol Imaging Biol 2004;6:183-187
25. Messa C, Bettinardi V, Picchio M, Pelosi E, Landoni C, Gianolli L, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging 2004;48:66-75
26. Pelosi E, Messa C, Sirioni S, Picchio M, Landoni C, Bettinardi V, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004;31:932-939
27. Cerfolio RJ, Ojha B, Bryant AS, Raghuvirve V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-1023
28. Costa DC, Visvikis D, Crosdale I, Pigden I, Townsend C, Bomanji J, et al. Positron emission and computed X-ray tomography: a coming together. Nucl Med Commun 2003;24:351-358
29. Lardinois D, Weder W, Hany TF, Kamel EM, Koron S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507
30. Bar-Shalom Y, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209
31. Hany TF, Steinert HC, Govers GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-581
32. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-37
Sung et al.

33. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy—initial experience. *Radiology* 2006;238:970-977

34. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? *Radiology* 2004;231:711-716

35. Bagheri B, Maurer AH, Cone L, Doss M, Adler L. Characterization of the normal adrenal gland with 18F-FDG PET/CT. *J Nucl Med* 2004;45:1340-1343

36. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. *Radiology* 1999;212:35-41

37. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. *AJR Am J Roentgenol* 1998;170:1369-1373